Melatonin in mental disorders: Treatment and prevention

Melatonin in the Promotion of Health: Second Edition

Volumn , Issue , 2011, Pages 311-326

  Maldonado, Maria D ^a   Pérez San Gregorio, Maria A ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885110090     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (145)

1. Liu, Y.J., Zhuang, J., Zhu, H.Y., Shen, Y.X., Tan, Z.L., Zhou, J.N. 2007. Cultured rat cortical astrocytes synthesize melatonin: Absence of diurnal rhythm. J Pineal Res 43: 232-238
2. Maldonado, M.D., Mora-Santos, M., Naji, L., Carrascosa-Salmoral, M.P., Naranjo, M.C., Calvo, J.R. 2010. Evidence of melatonin synthesis and release in mast cells. Possible modulator role on inflammation. Pharmacol Res 62: 282-287
3. Agez, L., Laurent, V., Guerrero, H.Y., Pévet, P., Masson-Pévet, M., Gauer, F. 2009. Endogenous melatonin provides an effective circadian message to both the suprachiasmatic nuclei and the pars tuberalis of the rat. J Pineal Res 46: 95-105
4. Maldonado, M.D., Siu, A.W., Sánchez-Hidalgo, M., Acuna-Castroviejo, D., Escames, G. 2006. Melatonin and lipid uptake by murine fibroblasts: Clinical implications. Neuroendocrinol Lett 27: 601-608
5. Maldonado, M.D., Murillo-Cabezas, F., Terron, M.P., Flores, L.J., Tan, D.X., Manchester, L.C., Reiter, R.J. 2007. The potencial of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res 42: 1-11
6. Maldonado, M.D., Murillo-Cabezas, F., Calvo, J.R., Lardone, P.J., Tan, D.X., Guerrero, J.M., Reiter RJ. 2007. Melatonin as pharmacologic support in burn patients: A proposed solution to thermal injury-related lymphocytopenia and oxidative damage. Crit Care Med 35: 1177-1185
7. Garcia-Navarro, A., Gonzalez-Puga, C., Escames, G., López, L.C., López, A., López-Cantarero, M. et al. 2007. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 43: 195-205
8. Reiter, R.J., Tan, D.X., Sainz, R., Mayo, J.C., Lopez-Burillo, S. 2002. Melatonin reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 54: 1299-1321
9. Ostrowska, Z., Ziora, K., Kos-Kudla, B., Swietochowska, E., Oswiecimska, J., Dyduch, A., Wolkowska-Pokrywa, K., Szapska, B. 2010. Melatonin, the RANKL/RANK/OPG system, and bone metabolism in girls with anorexia nervosa. Endokrynol Pol 61: 117-23
10. Reiter, R.J, Tan, D.X., Maldonado, M.D. 2005. Melatonin as an antioxidant: Physiology versus pharmacology. J Pineal Res 39: 215-216
11. Tomas-Zapico, C., Coto-Montes, A. 2005. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 39: 99-104
12. Pacchierotti, C., Iapichino, S., Bossini, L., Pieraccini, F., Castrogiovanni, P. 2001. Melatonin in psychiatric disorders: A review on the melatonin involvement in psychiatry. Front Neuroendocrinol 22: 18-32
13. Srinivasan, V., Smits, G., Kayumov, L., Pandi-Perumal, S.R., Cardinali, D.P., Thorpy, M.J. 2006. Melatonin in circadian rhythm sleep disorders. Neuroendocrine Correlates of Sleep-Wakefulness 269-294. New York: Springer
14. Chrousos, G.P. 2009. Stress and disorders of the stress system. Nat Rev Endocrinol 5: 374-381
15. Lakhan, S.E., Vieira, K.F. 2008. Nutritional therapies for mental disorders. Nutrition J 7: 1-8
16. Chakroun, N., Doron, J., Swendsen, J. 2004. Substance use, affective problems and personality traits: Test of two association models. Encephale 30: 564-569
17. Haynes, J.C., Farrell, M., Singleton, N., Araya, R., Lewis, G., Wiles, N.J. 2007. Alcohol consumption as a risk factor for non-recovery from common mental disorder: Results from the longitudinal follow-up of the National Psychiatric Morbidity Survey. Psychol Med 1: 1-5
18. Rosenthal, N.E., Sack, S.A., Gillin, J.C. 1984. Seasonal affective disorder. A description of the syndrome and preliminary finding with light therapy. Arch Gen Psychiatr 41: 72-80
19. Morera, A.L., Abreu, P. 2006. Seasonality of psychopathology and circannual melatonin rhythm. J Pineal Res 41: 279-283
20. Reiter, R.J. 2003. Melatonin: Clinical relevance. Best Practice Res Clin Endocrinol Metab 17: 273-285
21. Witt-Enderby, P.A., Radio, N.M., John, S., Vicki, L.D. 2006. Therapeutic treatments potentially mediated by melatonin receptors: Potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 41: 297-305
22. Garcia-Pergañeda, A., Pozo, D., Guerrero, J.M., Calvo, J.R. 1997. Signal transduction for melatonin in human lymphocytes. Involvement of a pertussis toxin-sensitive G protein. J Immunol 159: 3774-3781
23. Garcia-Mauriños, S., Gonzalez-Haba, M.G., Calvo, J.R., Goberna, R., Guerrero, J.M. 1998. Involvement of molecular binding sites for melatonin in the regulation of, IL-2 and, IL-6 production by human blood mononuclear cells. J Neuroimmunol 92: 76-84
24. Garcia-Mauriños, S., Pozo, D., Calvo, J.R., Guerrero, J.M. 2000. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res 29: 129-137
25. Leonard, B.E., Song, C. 1996. Stress and the immune system in the etiology of anxiety and depression. Pharmacol Biochem Behav 54: 299-303
26. Maldonado, M.D., Perez-Sangregorio, M.A., Reiter R.J. 2009. The role of melatonin in the immuno-neuro-psychology of mental disorders. Recent Pat CNS Drug Discov 4: 61-69
27. Maldonado, M.D., Reiter, R.J., Perez-Sangregorio, M.A. 2009. Melatonin as a potential therapeutic agent in psychiatric illness. Hum Psychopharmacol Clin Exp 24: 391-400
28. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (DSM-IV). American Psychiatric Press, Washington, DC
29. Ancoli-Israel, S., Martin, J.L. 2006. Insomnia and daytime napping in older adults. J Clin Sleep Med 2: 333-342
30. Perlis, M.L., Giles, D.E., Buysse, D.J., Tu, X., Kupfer, D.J 1997. Self-reporter sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42: 209-212
31. Basta, M., Chrousos, G.P., Vela-Bueno, A., Vgontzas, A.N. 2007. Chronic insomnia and the stress system. Sleep Med Clin 2: 279-291
32. Vgontzas, A.N., Liao, D., Bixler, E.O., Chrousos, G.P., Vela-Bueno, A. 2009. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep 32: 491-497
33. Benson, K.L. 2006. Sleep in schizophrenia: Impairments, correlates, and treatment. Psychiatr Clin North Am 29: 1033-1045
34. Srinivasan, V., Pandi-Perumal, S.R., Trakht, I., Spence, D.W., Hardeland, R., Poeggeler, B., Cardinali, D.P. 2009. Pathophysiology of depression: Role of sleep and the melatonergic system. Psychiat Res 165: 201-214
35. Zee, P.C., Manthena, P. 2007. The brain's master circadian clock: Implications and opportunities for therapy of sleep disorders. Sleep Medicine Reviews 11: 59-70
36. Ducovich, M.L., Markowska, M. 2005. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 27: 101-110
37. Liu, C., Weaver, D.R., Jin, X., Shearman, L.P., Pieschl, R.L., Gribkoff, V.K., Reppert, S.M. 1997. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19: 91-102
38. Kayumov, L., Brown, G., Jindal, R., Buttoo, K., Shapiro, C.M. 2001. A randomized double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep. Psychosom Med 63: 40-48
39. Wyatt, J.K., Dijk, D.J., Ritz-de Cecco, A., Ronda, J.M., Czeisler, C.A. 2006. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 29: 609-618
40. Garzón, C., Guerrero, J.M., Aramburu, O., Guzmán, T. 2009. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: A randomized, double-blind, placebo-controlled study. Aging Clin Exp Res 21: 38-42
41. Rahman, S.A., Kayumov, L., Shapiro, C.M. 2010. Antidepressant action of melatonin in the treatment of delayed sleep phase syndrome. Sleep Med 11: 131-136
42. Leonard, B.E., Song, C. 2002. Changes in the immune system in rodent models of depression. Int J Neuropsychopharmacol 5: 345-356
43. Muller, N., Schwarz, M.J. 2007. The immunological basis of glutamatergic disturbance in schizophrenia: Towards an integrated view. J Neural Transm Suppl 72: 269-280
44. Frieling, H., Hillemacher, T., Demling, J.H., Kornhuber, J., Bleich, S. 2007. New options in the treatment of depression. Fortschr Neurol Psychiatr 75: 3-16
45. Shelton, R.C., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D.A., Mirnics, K. 2010. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry, doi:10.1038/mp.2010.52
46. Muller, N., Schwarz, M.J. 2007. Inmunological aspects of depressive disoders. Nervenarzt 78: 1261-1273
47. Mcintyre, R.S., Soczynska, J.K., Konarski, J.Z., Woldeyohannes, H.O., Law, C.W., Miranda, A. et al. 2007. Should depressive syndromes be reclassified as "metabolic syndrome type II"? Ann Clin Psychiatry 19: 257-264
48. Leonard, B.E. 2006. HPA and immune axes in stress: Involvement of the serotonergic system. Neuroimmunomodulation 13: 268-276
49. Leonard, B.E., Myint, A. 2006. Inflammation and depression: Is there a causal connection with dementia? Neurotox Res 10: 149-160
50. Bruce, L.R. 2007. Worried sick: Antidepressants, stress and inflammation. J Clin Psychiatry 68: 10
51. Srinivasan, V. Smits, M., Spence, W., Lowe, A.D., Kayumov, L., Pandi-Perumal S.R. 2006. Melatonin in mood disorders. World J Biol Psychiatry 7: 138-151
52. Castanon, N., Leonard, B.E., Neveu, P.J., Yirmiya, R. 2002. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 16: 569-574
53. Leonard, B.E., Myint, A. 2009. The psychoneuroimmunology of depression. Hum Psychopharmacol Clin Exp, doi:10.1002/hup.1011
54. Myint, A.M., Leonard, B.E., Steinbusch, H.W., Kim, Y.K. 2005. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 88: 167-173
55. Leonard, B.E. 2007. Psychopathology of depression. Drugs Today 43: 705-716
56. Szuster-Ciesielska, A., Slotwinska, M., Stachura, A. Marmurowska-Michalowska, H., Dubas-Slemp, H., Bojarska-Junak, A., Kandefer-Szerszen, M. 2008. Accelerated apoptosis of blood leucocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32: 686-694
57. Darko, D.F., Rose, J., Gillin, J.C., Golshan, S., Baird SM. 1988. Neutrophilia and lymphopenia in major mood disorders. Psychiatry Res 25: 243-251
58. Godbout, J.P., Glaser, R. 2006. Stress-induced immune dysregulation: Implications for wound healing, infectious disease and cancer. J Neuroimmune Pharmacol 1: 421-427
59. Vaccarino, V., Johnson, B.D., Sheps, D.S., Reis, S.E., Kelsey, S.F., Bittner, V. et al. 2007. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: The National Heart, Lung and Blood Institute-sponsored WISE study. J Am Coll Cardiol 50: 2044-2050
60. Holsboer, F., Ising, M. 2008. Central CRH system in depression and anxiety. Evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583: 350-357
61. Carrillo-Vico. A., Lardone, P.J., Naji, L., Fernández-Santos, J.M., Martín-Lacave, I., Guerrero, J.M., Calvo, J.R. 2005. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: Regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and antiapoptotic effects. J. Pineal Res 39: 400-408
62. Carrillo-Vico, A., Lardone, P.J., Fernández-Santos, J.M., Martín-Lacave, I., Calvo, J.R, Karasek, M., Guerrero, J.M. 2005. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin 2/interleukin 2 receptor system. J Clin Endocrinol Metab 90: 992-1000
63. Gitto, E., Reiter, R.J., Amodio, A., Romeo, C., Cuzzocrea, E., Sabatino, G. et al. 2004. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 36: 250-255
64. Gitto, E., Reiter, R.J., Cordaro, S.P., La Rosa, M., Chiurazzi, P., Trimarchi, G. et al. 2004. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: Beneficial effects of melatonin. Am J Perinatol 21: 209-216
65. Gitto, E., Reiter, R.J., Sabatino, G., Buonocore, G., Romeo, C., Gitto, P. et al. 2005. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: Improvement with melatonin treatment. J Pineal Res 39: 287-293
66. Tan, D.X., Manchester, L.C., Terron, M.P. Flores, L.J., Reiter, R.J. 2007. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species. J Pineal Res 42: 28-42
67. Borda, M., Pérez-San-Gregorio, M.A., Blanco A. 2000. Conduct modification techniques manual in behavioral medicine. Publications of the University of Seville 1: 63-117
68. Roger, M.P. 2007. New antidepressant or more of the same? Neuropsychiatric disease and treatment. Editorial Foreword 3-5
69. Rapaport, M.H., 2007. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: The state of the art. J Clin Psychiatry 68: 42-46
70. Zupancic, M., Guilleminault, C. 2006. Agomelatine: A preliminary review of a new antidepressant. CNS Drugs 20: 981-992
71. Pandi-Perumal, S.R., Trakht, I., Srinivasan, V., Spence, D.W., Poeggler, B., Harderland, R., Cardinali, D.P. 2009. The effect of melatonergic and non-melatonergic antidepressants on sleep: Weighing the alternatives. World J Biol Psychiatry 10: 342-354
72. Battaglino, R., Vokes, M., Schulze, S., Sharma, A., Graves, D., Kohler, T. et al. 2007. Fluoxetine treatment increases trabecular bone formation in mice (fluoxetine affects bone mass). J Cell Biochem 10: 1387-1394
73. Diem, S.J., Blackwell, T.L., Stone, K.L., Yaffe, K., Haney, E.M., Bliziotes, M.M., Ensrud, K.E. 2007. Use of antidepressnts and rates of hip bone loss in older women. Arch Intern Med 167: 1240-1245
74. Haney, E.M., Chan, B.K., Diem, S.J., Ensrud, K.E., Cauley, J.A., Barrett-Connor, E. et al. 2007. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167: 1231-1232
75. Tan, D.X., Manchester, L.C., Reiter, R.J., Qi, W.B., Zhang, M., Weintraub, S.T., Cabrera, J., Sainz, R.M., Mayo, J.C. 1999. Identification of highly elevated levels of melatonin in bone marrow: Its origin and significance. Biochim Biophys Acta 1472: 206-214
76. Cardinali, D.P., Ladizesky, M.G., Boggio, V., Cutrera, R.A., Mautalen, C. 2003. Melatonin effects on bone: Experimental facts and clinical perspective. J Pineal Res 34: 81-87
77. Radio, N.M., Doctor, J.S., Witt-Enderby, P.A. 2006. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grow in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signalling cascade. J Pineal Res 40: 332-342
78. Sánchez-Hidalgo, M., Lu, Z., Tan, D.X., Maldonado, M.D., Reiter, R.J., Gregerman, R.I. 2007. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS 17/2.8 cells: Implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol 292: 2208-2215
79. Lipartiti, M., Franceschini, D., Zanoni, R., Gusella, M., Giusti, P., Cagnoli, C.M. et al. 1996. Neuroprotective effects of melatonin. Adv Exp Med Biol 398: 315-321
80. Simko, F., Paulis, L. 2007. Melatonin as a potential antihypertensive treatment. J Pineal Res 42: 319-322
81. Hirsch-Rodriguez, E., Imbesi, M., Manev, R., Uz, T., Manev, H. 2006. The pattern of melatonin receptor expression in the brain may influence antidepressant treatment. Med Hypotheses 69: 120-124
82. Imbesi, M., Uz, T., Yildiz, S. 2006. Drug and region-specific effects of protracted antidepressant and cocaine treatment on the content of melatonin MT1 and MT2 receptor mRNA in the mouse brain. Int J Neuroprotect Neuroregen 2: 185-189
83. Judd, L.L., Akiskal, H.S. 2003. The prevalence and disability of bipolar spectrum disorders in the US population: Re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 73: 123-131
84. Mcintyre, R.S., Muzina, D.J., Kemp, D.E., Blank, D., Woldeyohannes, H.O., Lofchy, J. et al. 2008. Bipolar disorder and suicide: Research synthesis and clinical translation. Curr Psychiatry Rep 10: 66-72
85. Kovacsics, C.E., Gottesman, I.I., Gould TD. 2009. Lithium's antisuicidal efficacy: Elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 49: 175-98
86. Rihmer, Z., Gonda, X., Rhimer, A. 2006. Creativity and mental illness. Psychiatr Hung 21: 288-294
87. Pandi-Perumal, S.R., Srinivasan, V., Maestroni, G.J., Cardinali, D.P., Poeggeler, B., Hardeland, R. 2006. Melatonin: nature's most versatile biological signal? FEBS J 273: 2813-2838
88. Lam, R.W., Bercowitz, A.L., Berga, S.L., Clark, C.M., Kripke, D.F., Gillin, J.C. 1990. Melatonin suppression in bipolar and unipolar mood disorders. Psychiatry Res 33: 129-134
89. Nurnberger, J.I., Adkins, S., Lahiri, D.K., Mayeda, A., Hu, K., Lewy, A. et al. 2000. Melatonin suppression by light in euthymic bipolar and unipolar. Arch Gen Psychiatry 57: 72-579
90. Lewy, A.J., Wehr, T.A., Gold, P.W., Goodwin, F.K. 1979. Plasma melatonin in manic-depressive illness. In: E. Usdin, I.J. Kopin, J. Barchas, eds: Catecholamines: Basic and Clinical Frontiers. Vol 2, 1173-1175. New York: Pergamon Press
91. Lewys, A.J., Wehr, T.A., Goodwin, F.K., Newsome, D.A., Rosenthal, N.E. 1981. Manic-depressive patients may be supersensitive to light. Lancet 1: 383-384
92. Maes, M., Scharpe, S., Bosmans, E., Vandewoude, M., Suy, E., Uyttenbroeck, W. et al. 1992. Disturbances in acute phase plasma proteins during melancholia: Additional evidence for the presence of an inflammatory process during that illness. Prog Psychopharmacol Biol Psychiatry 16: 501-515
93. Wadee, A.A., Kuschke, R.H., Wood, L.A., Berk, M., Ichim, L., Maes M. 2002. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol 17: 175-179
94. Tsai, S.Y., Lee, H.C., Chen, C.C., Huang, Y.L. 2007. Cognitive impairment in later life in patients with early-onset bipolar disorders. Bipolar Disord 9: 868-875
95. Kim, Y.K., Myint, A.M., Lee, B.H., Han, C.S., Lee, S.W., Leonard, B.E., Steinbusch, H.W. 2004. T-helper types 1,2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 129: 267-272
96. Maes, M., Bosmans, E., Calabrese, J., Smith, R., Meltzer, H.Y. 1995. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J Psychiatr Res 29: 141-152
97. Song, C., Horrobin, D.F., Leonard, B.E. 2006. The comparison of changes in behaviour, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1β in rats. Pharmacopsychiatry 39: 88-99
98. van Winkel, R., De Hert, M., Van Eyck, D., Hanssens, L., Wampers, M., Scheen, A., Peuskens, J. 2008. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 10: 342-348
99. Zorrilla, Z.M. 2003. Mechanism of action of lithium: Intracellular signalling pathways. Vertex 14: 45-52
100. Geddes, J.R., Burgess, S., Hawton, K., Jamison, K., Goodwin, G.M. 2004. Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 161: 217-222
101. Surman, O.S. 1993. Possible immunological effects of psychotropic medication. Psychosomatics 34: 139-143
102. Yolken, R.H., Torrey, E.F. 1995. Viruses, schizophrenia, and bipolar disorders. Clin Microbiol Rev 8: 131-145
103. Teixeira, P.J., Rocha, F.L. 2007. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 29: 330-336
104. van Winkel, R., De Hert, M., Wampers, M., Van Eyck, D., Hanssens, L., Scheen, A., Peuskens, J. 2008. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 69: 472-479
105. Molina-Carballo, A., Muñoz-Hoyos A., Reiter, J.R., Sánchez-Forte, M., Moreno-Madrid, F., Rufo-Campos, M. et al. 1997. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: Two years experience. J Pineal Res 23: 97-105
106. Kabuto, H., Yokoi, I., Ogawa, N. 1998. Melatonin inhibits iron-induced epileptic discharges in rats by suppressing peroxidation. Epilepsia 39: 237-243
107. Reiter, R.J., Tan, D.X., Terron, M.P., Flores, L.J., Czarnocki, Z. 2007. Melatonin and its metabolites: New findings regarding their production and their radical scavenging actions. Acta Biochem Pol 54: 1-9
108. Reiter, R.J., Benitez-King G. 2009. Melatonin reduces neuronal loss and cytoskeletal deterioration: Implications for psychiatry. Mental health 32: 3-11
109. Hung, M.W., Tipoe, G.L., Poon, A.M. 2008. Protective effect of melatonin against hippocampal injury of rats with intermittent hypoxia. J Pineal Res 44: 214-221
110. Ramirez-Rodriguez, G., Klempin, F., Babu, H., Benitez-Kin, G., Kempermann G. 2009. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacol 34: 2180-2191
111. Fagiolini, A., Frank, E., Scott, J.A., Turkin, S., Kupfer, D.J. 2005. Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 7: 424-430
112. Simko, F., Paulis, L. 2008. Chronotherapy beyond blood pressure reduction? J Pineal Res 45: 227-228
113. Moriya, T., Horie, N., Mitome, M., Shinohara, K. 2007. Melatonin influences the proliferative and differentiative activity of neural stem cells. J Pineal Res 42: 411-418
114. Gutierrez-Cuesta, J., Sureda, F.X., Romeu, M., Canudas, A.M., Caballero, B., Coto-Montes, A. et al. 2007. Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8. J Pineal Res 42: 394-402
115. Tengattini, S., Reiter, R.J., Tan, D.X., Terron, M.P., Rodella, L.F., Rezzani, R. 2008. Cardiovascular diseases: Protective effects of melatonin. J Pineal Res 44: 16-25
116. Dowling, G.A., Burr, R.L., Van Someren, E.J., Hubbard, E.M., Luxenberg, J.S., Mastick, J., Cooper, B.A. 2008. Melatonin and bright-light treatment for rest activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc 56: 239-246
117. Dallaspezia, S., Benedetti, F. 2009. Melatonin, circadian rhythms, and the clock genes in bipolar disorder. Curr Psychiatry Rep 11: 488-493
118. Robertson, J., Peter, E. 1997. Case study: The use of melatonin in a boy with refractory bipolar disorder. J Am Acad Child Adolesc Psychiatry 36: 822-825
119. Bersani, G., Garavini, A. 2000. Melatonin add-on in manic patients with treatment resistant insomnia. Prog Neuropsychopharmacol Biol Psychiatry 24: 185-191
120. Gao, K., Calíbrese, J.R. 2005. Newer treatment studies for bipolar depression. Bipolar Disord 5: 13-23
121. Nierenberg, A.A. 2009. Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression. Psychother Psychosom 78: 391-393
122. Gonzalez-Maeso, J., Ang, R.L., Yuen, T., Chan, P., Weisstaub, N.V., López-Giménez, J.F. et al. 2008. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452: 38-39
123. Walsh, T., McClellan, J., McCarthy, S.E., Addington, A.M., Pierce, S.B., Cooper, G.M., Nord, A.S. et al. 2008. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320: 539-543
124. Shao, L., Vawter, M.P. 2008. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry 64: 89-97
125. van der Heijden, F.M., Fekkes, D., Tuinier, S., Sijben, A.E., Kahn, R.S., Verhoeven, W.M. 2005. Amino acids in schizophrenia: Evidence for coger tryptophan availability during treatment with atypical antipsychotics? J Neural Transm 112: 577-585
126. Baskak, S.C., Ozsan, H., Baskak, B., Devrimci, O.H., Kinikli G. 2008. Peripheral blood T-lymphocyte and T-lymphocyte subset ratios before and after treatment in schizophrenia patients not taking antipsychotic medication. Turk Psikiyatri Derg 19: 5-12
127. Koliaskina, G.I., Sekirina, T.P., Androsova, L.V., Kushner, S.G., Vasil'eva, E.F., Burbaeva, O.A., Morozova, M.A. 2007. The influence of atypical neuroleptics on the immune system of patient with schizophrenia. Vestn Ross Med Nauk 3: 14-19
128. Na, K.S., Kim, Y.K. 2007. Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 56: 55-63
129. Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., Kouassi, E. 2008. Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry 63: 801-808
130. Oken, R.J. 1995. Towards a unifiying hypothesis of neurodegenerative diseases and a concomitant rational strategy for their prophylaxis and therapy. Med Hypotheses 45: 341-342
131. Oken, R.J. 2001. Obsessive-compulsive disorder: A neuronal membrane phospholipids hypothesis and concomitant therapeutic strategy. Med Hypotheses 56: 413-415
132. Reiter, R.J., Tan, D.X., León, J. et al. 2005. When melatonin gets on your nerves: Its beneficial actions in experimental models of stroke. Exp Biol Med 230: 104-117
133. Mattias, W., Zellweger, R., DeMaso., Ayala, A., Chaudry, I.H. 1996. Melatonin administration attenuates depressed immune functions after trauma-hemorrhage. J Surg Res 63: 256-262
134. Suresh-Kumar, P.N., Andrade, C., Bhakta, S.G., Singh, N.M. 2007. Melatonin in schizophrenic outpatients with insomnia: A double-blind, placebo-controlled study. J Clin Psychiatry 68: 237-241
135. Hocaoglu, C. 2009. Clozapine-induced rabbit syndrome: A case report. Mental Illness 1: 1-3
136. Newcomer, J.W. 2005. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 1: 1-93
137. Casademont, J., Garrabou, G., Miró, O., López, S., Pons, A., Bernardo, M., Cardellach, F. 2007. Neuroleptic treatment effect on mitochondrial electron transport chain: Peripheral blood mononuclear cells analysis in psychotic patients. J Clin Psychopharmacol 27: 284-288
138. Paredes, S.D., Terrón, M.P., Valero, V., Barriga, C., Reiter, R.J., Rodríguez, A.B. 2007. Orally administered melatonin improves nocturnal rest in young and old ringdoves. Basic Clin Pharmacol Toxicol 100: 258-268
139. Shamir, E., Rotenberg, V.S., Laudon, M., Zisapel, N., Elizur, A. 2000. First-night effects of melatonin treatment in patients with chronic schizophrenia. J Clin Psychopharmacol 20: 691-694
140. Shamir, E., Barak, Y., Shalman, I., Laudon, M., Zisapel, N., Tarrasch, R. et al. 2001. Melatonin treatment in tardive dyskinesia: A double-blind, placebo-controlled, crossover study. Arch Gen Psychiatr 58: 1049-1052
141. Zipris, P., Melamed, Y., Weizman, A., Bleich, A. 2007. Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies. Isr J Psychiatry Relat Sci 44: 54-56
142. Wolden-Hanson, T., Mitton, D.R., McCants, R.L., Yellon, S.M., Wilkinson, C.W., Matsumoto, A.M., Rasmussen, D.D. (2000). Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 141:487-497
143. Cheung, R.T., Tipoe, G.L., Tam, S., Ma, E.S., Zou, L.Y., Chan, P.S. 2006. Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res 41: 337-343
144. Pignone, A.M., Rosso, D.A., Fiori, G., Matucci-Cerinic, M., Becucci, A., Tempestini, A. et al. 2006. Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarcoidosis. J Pineal Res 41: 95-100
145. Serfaty, M.A., Osborne, D., Buszewicz, M.J., Blizard, R., Raven, P.W. 2010. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol 25: 132-142